SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant community traction as investors anticipate the imminent 80th event trigger for its REGAL Phase 3 clinical trial in acute myeloid leukemia, which is viewed as a pivotal catalyst for the company's valuation. Market participants are actively debating the potential for GPS to deliver curative outcomes, with many highlighting institutional accumulation and management's recent optimistic commentary on the trial's survival data as key drivers behind the bullish sentiment.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to favorable comparative clinical data highlighting the efficacy of its bladder cancer therapy against current market treatments, fueling community debate over the company's competitive positioning and regulatory outlook. Discussions are heavily focused on the stock's significant short interest and the anticipation of upcoming clinical data releases, which supporters believe will serve as a major catalyst for a price re-rating.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust (SLV) is facing intense volatility as the market reacts to a broader bond sell-off and rising Treasury yields, which are pressuring precious metals. While some in the community view the current drawdown as a buying opportunity based on long-term supply deficits, others are aggressively shorting the asset, debating whether the recent price surge was a sustainable trend or a temporary bubble.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Investors are maintaining a cautious but speculative stance on NVDA as the market awaits earnings, with the community actively debating whether the stock will break higher or succumb to a "sell the news" correction. The primary focus for traders is the potential for significant market-wide volatility, as participants attempt to gauge demand for AI infrastructure and data-center revenue while hedging against broader macroeconomic uncertainties.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is currently trending following a strong quarterly earnings report that featured a beat on top and bottom lines, alongside raised fiscal year guidance that signaled continued confidence in the restaurant's expansion and same-store sales growth. The community remains heavily divided between bulls celebrating the company's rapid growth as the next major fast-casual success story and bears who argue the stock's valuation is detached from fundamentals given current macroeconomic headwinds.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users express intense polarization over the stock's performance, fueled by ongoing debates about the company's financial stability and its founder's political influence. Community discussions are highly contentious, with participants clashing over federal settlements, controversial policy moves, and skepticism regarding the long-term viability of the asset.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is under heavy downward pressure, recently hitting 52-week lows, as investors react to leadership changes, weaker-than-expected guidance, and broader concerns regarding consumer spending on non-essential pet items. While many in the community remain frustrated by the consistent price decline, some investors see the current valuation as a compelling opportunity to average down, citing the company's strong Autoship model, lack of debt, and loyal customer base as long-term strengths.

Keysight Technologies, Inc. engages in the provision of electronic design and test solutions that are used in the design, development, manufacture, installation, deployment, validation, optimization, and secure operation of electronics systems to communications, networking, and electronics industries. It operates through the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The CSG segment serves customers spanning the global commercial communications and aerospace, defense, and government end markets. The EISG segment offers test and measurement solutions across electronic industrial end markets, focusing on applications in the automotive, and energy industry and measurement solutions for semiconductor design and manufacturing, consumer electronics, education, and general electronics manufacturing. The company was founded by William R. Hewlett and David Packard in 1937 and is headquartered in Santa Rosa, CA.

Keysight Technologies Inc

Keysight Technologies is seeing significant market activity as investors weigh strong earnings and revenue performance against concerns over the company's forward guidance and broader macroeconomic headwinds. The community is actively debating whether the stock's recent volatility represents a structural buying opportunity or a signal to remain cautious amid cyclical shifts in demand.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is currently facing intense volatility as the community reacts to a high-stakes trade summit in China, where expectations for a massive jet order have collided with conflicting reports on the actual deal size. Investors remain deeply divided, debating whether the stock is a long-term industrial turnaround opportunity with a massive backlog or a victim of persistent market manipulation and geopolitical headwinds.

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Monopar Therapeutics Inc

Monopar Therapeutics is trending as investors react to the company's recent publication of positive Phase 2 study results, which demonstrate that its candidate, ALXN1840, effectively improves copper balance in Wilson disease patients. The community is actively discussing the drug's regulatory progress toward a planned NDA filing, while analysts continue to adjust their outlooks based on this potential de-risking of the company's clinical pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$DBRG I don&#39;t think anybody has read the Preferred Shares change of control provisions specifically for Series I &amp; J or waiting for the proxy statement!

David

Brian

All $DBRG preferred stocks down 15% in 5 trading sessions, on heavy volume, while common remains flat. Someone wants out at any cost.

StockTwits Web

DigitalBridge Group Inc - Ordinary Shares - Class A

Jose

StockTwits for iOS

 I don't think anybody has read the Preferred Shares change of control provisions specifically for Series I & J or waiting for the proxy statement!